This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

At NeoPharm, the Buck Stops Before Kapoor

Kapoor wants shareholders to remove directors Sander Flaum, Erick Hanson (who replaced Kapoor as chairman), Matthew Rogan and Kaveh Safavi -- each of whom is deemed independent, according to the company.

In their place, Kapoor has nominated three new directors -- Brian Tambi, Ronald Eidell and Bernard Fox. Kapoor and current CEO Greg Young would remain directors.

As noted above, given the sorry state of NeoPharm these days, investors seem justified in questioning the competence of the current board. But it seems disingenuous for Kapoor to say that, somehow, he hasn't also been responsible for the company's many screwups. He is a founder and the largest shareholder, after all, and served as the company's chairman.

Kapoor could not be reached for comment. But his spokesman Michael Babich says Kapoor, as chairman, tried to take the company in another direction, but was often overruled by the other directors. Kapoor "has been chairman, but that did not give him the authority to overrule the board. His vote counts only once, just like the other directors," Babich said, adding that "this is why Kapoor is being forced to take this action."

Kapoor's slate of chosen directors does not appear to be entirely independent. Tambi is currently CEO and chairman of privately held Morton Grove Pharmaceuticals. But from 1986 to 1990, Tambi worked for Kapoor at Lyphomed, which Kapoor eventually sold to Japanese drugmaker Fujisawa. (Tambi stayed on at Fujisawa for another two years.) After the deal closed, Fujisawa sued Kapoor for fraud under the federal civil racketeering statute; the case was eventually settled in 1999 under confidential terms.

A second Kapoor nominee, Bernard Fox, has also served as a consultant to the company.

And under Kapoor's previous leadership as chairman, NeoPharm has fallen far short of good corporate governance practices. The SEC first informed NeoPharm that it was under investigation in March, but this fact wasn't disclosed publicly until May.

Kapoor doesn't pull down a salary from NeoPharm, but the company has paid $125,000 each year to EJ Financial Services, a health care consulting firm owned by Kapoor. According to his SEC filing, Kapoor says those payments have now been stopped. Last year, NeoPharm helped bail out Akorn (AKRN), a specialty drugmaker delisted by Nasdaq in which Kapoor is also the chairman and majority shareholder.

For its part, current NeoPharm management disagrees with Kapoor's action and intends to fight to retain the company's current slate of directors. If anything, this looming shareholder battle will only serve to distract the company further from developing its pipeline drugs.

Adam Feuerstein writes regularly for RealMoney.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. He invites you to send your feedback to adam.feuerstein@thestreet.com.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
PFE $34.21 -0.32%
AAPL $126.88 -1.40%
FB $77.78 -1.30%
GOOG $534.50 -1.20%
TSLA $231.69 0.51%

Markets

DOW 18,018.32 -52.08 -0.29%
S&P 500 2,100.16 -14.33 -0.68%
NASDAQ 4,959.1250 -57.8040 -1.15%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs